GlaxoSmithKline will pay billions of dollars to US authorities after admitting charges of healthcare fraud.

The company – whose consumer brands include Lucozade, Horlicks, Ribena and Macleans toothpaste – will pay $3bn (£1.91bn) to settle charges relating to its aggressive marketing of antidepressants.

In court documents, GSK was said to have wooed doctors with lavish hospitality and cash payments in order to promote the use of a number of drugs.

“Today brings to resolution difficult, long-standing matters for GSK,” said chief executive Sir Andrew Witty.

“I want to express our regret and reiterate that we have learnt from the mistakes that were made.  In the US, we have taken action at all levels in the company. We have fundamentally changed our procedures for compliance, marketing and selling. When necessary, we have removed employees who have engaged in misconduct.”